Journal of Nanobiotechnology,
Journal Year:
2024,
Volume and Issue:
22(1)
Published: June 21, 2024
Abstract
Background
Cancer
recurrence
following
surgical
resection
is
a
major
cause
of
treatment
failure.
Finding
effective
methods
to
prevent
postoperative
and
wound
infection
an
important
component
successful
surgery.
With
the
development
new
nanotechnology,
more
options
have
been
provided
for
adjuvant
therapy.
This
study
presents
innovative
hydrogel
system
that
stimulates
tumoricidal
immunity
after
non-small
cell
lung
cancer
(NSCLC)
prevents
relapse.
Results
The
based
on
excellent
photothermal
conversion
performance
single-atom
platinum
(CN-Pt)
along
with
delivery
release
chemotherapy
drug,
gemcitabine
(GEM).
coated
onto
surface
tumor
removal
subsequent
near-infrared
(NIR)
therapy,
which
efficiently
induces
necroptosis
residual
cells,
amplifies
levels
damage-associated
molecular
patterns
(DAMPs),
increases
number
M1
macrophages.
significantly
higher
phagocytic
macrophages
enhance
immunogenicity
sensitize
cells
CD8
+
T-cell
control
recurrence,
has
verified
using
animal
model
recurrence.
CN-Pt-GEM-hydrogel
NIR
can
also
inhibit
infection.
Conclusions
These
findings
introduce
alternative
strategy
supplementing
antitumor
in
patients
undergoing
NSCLC
tumors.
exhibits
good
biosafety
may
be
adaptable
clinical
application
relation
surgery,
tissue
filling,
prevention,
prevention.
Biomedicine & Pharmacotherapy,
Journal Year:
2023,
Volume and Issue:
164, P. 114954 - 114954
Published: May 29, 2023
Traditionally,
vaccines
have
helped
eradication
of
several
infectious
diseases
and
also
saved
millions
lives
in
the
human
history.
Those
prophylactic
acted
through
inducing
immune
responses
against
a
live
attenuated,
killed
organism
or
antigenic
subunits
to
protect
recipient
real
infection
caused
by
pathogenic
microorganism.
Nevertheless,
development
anticancer
as
valuable
targets
health
has
faced
challenges
requires
further
optimizations.
Dendritic
cells
(DCs)
are
most
potent
antigen
presenting
(APCs)
that
play
essential
roles
tumor
immunotherapies
induction
CD8+
T
cell
immunity.
Accordingly,
various
strategies
been
tested
employ
DCs
therapeutic
for
exploiting
their
activity
cells.
Application
whole
purified/recombinant
peptides
common
approaches
pulsing
DCs,
which
then
injected
back
into
patients.
Although
some
hopeful
results
reported
number
DC
animal
clinical
trials
cancer
patients,
such
still
inefficient
require
optimization.
Failure
vaccination
is
postulated
due
immunosuppressive
microenvironment
(TME),
overexpression
checkpoint
proteins,
suboptimal
avidity
tumor-associated
(TAA)-specific
lymphocytes,
lack
appropriate
adjuvants.
In
this
review,
we
an
overview
current
experiments
evaluated
efficacy
well
focusing
on
improve
potential
including
combination
therapy
with
inhibitors
(ICIs).
Science Advances,
Journal Year:
2025,
Volume and Issue:
11(1)
Published: Jan. 1, 2025
Human
mesenchymal
stem
cells
(hMSCs)
respond
to
mechanical
stimuli,
including
stiffness
and
viscoelasticity.
To
date,
it
is
unknown
how
extracellular
fluid
viscosity
affects
hMSC
function
on
substrates
of
different
While
hMSCs
assume
an
adipogenic
phenotype
gels
low
prescribed
stress
relaxation
times,
elevated
sufficient
bias
toward
osteogenic
phenotype.
Elevated
induces
Arp2/3-dependent
actin
remodeling,
enhances
NHE1
activity,
promotes
spreading
via
up-regulation
integrin-linked
kinase.
The
resulting
increase
in
membrane
tension
triggers
the
activation
transient
receptor
potential
cation
vanilloid
4
facilitate
calcium
influx,
thereby
stimulating
RhoA/ROCK
driving
YAP-dependent
RUNX2
translocation
nucleus,
leading
differentiation.
soft
at
relative
basal
favor
M2
macrophage
This
study
establishes
as
a
key
physical
cue
that
imprints
memory
immunosuppressive
Biomedicine & Pharmacotherapy,
Journal Year:
2022,
Volume and Issue:
156, P. 113906 - 113906
Published: Oct. 25, 2022
Tumor
microenvironment
(TME)
takes
critical
roles
in
tumor
resistance
to
immune
checkpoint
inhibitors
(ICIs)
including
anti-programmed
death-1
(PD-1)
or
death-ligand
1
(PD-L1).
Cancer
stem
cells
(CSCs)
are
one
of
the
key
components
TME
that
play
important
immunoregulation
and
therapy
resistance.
CSCs
suppress
CD8+
T
cell
infiltration,
promote
recruitment
type
2
macrophages
(M2)
activity
neutrophils
(N2).
There
is
a
positive
association
between
CSC
expansion
with
high
PD-L1
expression
TME,
higher
than
cancer
cells.
metastatic
induces
dedifferentiation
program
through
stimulating
an
epithelial-mesenchymal
transition
(EMT)
profile,
thereby
replenishing
proportion
inside
tumor.
Conversion
from
EMT
mesenchymal-epithelial
(MET)
downregulates
on
non-CSCs
increases
ICI
efficacy.
evidence
replenishment
secondary
anti-PD-1
therapy.
Targeting
is,
fact,
step
effective
breakdown
reducing
recurrence
after
immunotherapy.
A
number
signaling
involved
enrichment
within
area,
among
them
focus
over
transforming
growth
factor-β
(TGF-β).
TGF-β
program,
its
as
bridge
increased
level
rationalizes
application
dual
TGF-β/anti-PD-L1
strategy
for
reinvigorating
immunoactivities
patients
under
In
this
review,
we
aimed
discuss
about
connections
ecosystem
impact
such
interactions
responses
Nano Convergence,
Journal Year:
2023,
Volume and Issue:
10(1)
Published: Aug. 7, 2023
Abstract
Cancer
immunotherapy,
which
harnesses
the
power
of
immune
system,
has
shown
immense
promise
in
fight
against
malignancies.
Messenger
RNA
(mRNA)
stands
as
a
versatile
instrument
this
context,
with
its
capacity
to
encode
tumor-associated
antigens
(TAAs),
cell
receptors,
cytokines,
and
antibodies.
Nevertheless,
inherent
structural
instability
mRNA
requires
development
effective
delivery
systems.
Lipid
nanoparticles
(LNPs)
have
emerged
significant
candidates
for
cancer
providing
both
protection
enhanced
intracellular
efficiency.
In
review,
we
offer
comprehensive
summary
recent
advancements
LNP-based
systems,
focus
on
strategies
optimizing
design
mRNA-encoded
therapeutics
treatment.
Furthermore,
delve
into
challenges
encountered
field
contemplate
future
perspectives,
aiming
improve
safety
efficacy
immunotherapies.
Graphical
Biomedicine & Pharmacotherapy,
Journal Year:
2023,
Volume and Issue:
163, P. 114890 - 114890
Published: May 15, 2023
B7
homolog
3
(B7-H3,
also
called
CD276)
is
a
checkpoint
of
family
that
aberrantly
and
consistently
expressed
in
several
human
cancers,
its
overexpression
correlates
with
weak
prognosis.
B7-H3
on
number
cells,
it
acts
as
driver
immune
evasion.
This
mediated
through
hampering
T
cell
infiltration
promoting
exhaustion
CD8+
cells.
Increased
activity
promotes
macrophage
polarity
toward
pro-tumor
type
2
(M2)
phenotype.
In
addition,
high
induces
aberrant
angiogenesis
to
promote
hypoxia,
result
which
resistance
common
inhibitor
(ICI)
therapy.
the
impact
hypoxia
dampening
recruitment
into
tumor
area.
The
immunosuppressive
property
offers
insights
targeting
this
desired
approach
cancer
immunotherapy.
can
be
target
blocking
monoclonal
antibodies
(mAbs),
combination
therapies,
chimeric
antigen
receptor-modified
(CAR-T)
cells
bispecific
antibodies.
Biomedicine & Pharmacotherapy,
Journal Year:
2023,
Volume and Issue:
162, P. 114639 - 114639
Published: April 1, 2023
Human
endogenous
retrovirus
H
long
terminal
repeat-associating
protein
2
(HHLA2
or
B7-H7)
is
a
newly
discovered
B7
family
member.
HHLA2
aberrantly
expressed
in
solid
tumors
and
exerts
co-stimulatory
co-inhibitory
activities
dependent
on
interaction
with
counter
receptors.
represents
effects
upon
transmembrane
immunoglobulin
domain
containing
(TMIGD2,
also
called
CD28H),
but
its
killer
cell
Ig-like
receptor,
three
Ig
domains
cytoplasmic
tail
3
(KIR3DL3)
renders
effects.
TMIGD2
mainly
resting
naïve
T
cells,
whereas
expression
of
KIR3DL3
occurs
activated
cells.
HHLA2/KIR3DL3
attenuates
responses
from
both
innate
adaptive
anti-tumor
immunity,
the
activity
within
this
axis
regarded
as
biomarker
weak
prognosis
cancer
patients.
promotes
CD8+
exhaustion
induces
macrophage
polarity
toward
pro-tumor
M2
phenotype.
diverse
profile
tumor
stroma.
Tumoral
presumably
higher
compared
programmed
death-ligand
1
(PD-L1),
co-expression
PD-L1
indicative
more
severe
outcomes.
A
suggested
strategy
patients
HHLA2high
to
use
monoclonal
antibodies
for
specifically
suppressing
inhibitory
receptor
KIR3DL3,
not
ligand.
can
be
target
development
agonistic
bispecific
hampering
resistance
death-1
(PD-1)/PD-L1
blockade
therapy.
Biomedicines,
Journal Year:
2023,
Volume and Issue:
11(9), P. 2411 - 2411
Published: Aug. 28, 2023
This
comprehensive
review
elucidates
the
intricate
roles
of
long
non-coding
RNAs
(lncRNAs)
within
colorectal
cancer
(CRC)
microenvironment,
intersecting
domains
immunity,
intercellular
communication,
and
therapeutic
potential.
lncRNAs,
which
are
significantly
involved
in
pathogenesis
CRC,
immune
evasion,
treatment
response
to
have
crucial
implications
inflammation
serve
as
promising
candidates
for
novel
strategies
biomarkers.
scrutinizes
interaction
lncRNAs
with
Consensus
Molecular
Subtypes
(CMSs)
their
complex
interplay
tumor
stroma
affecting
immunity
inflammation,
conveyance
via
extracellular
vesicles,
particularly
exosomes.
Furthermore,
we
delve
into
relationship
between
other
RNAs,
including
microRNAs
circular
mediating
cell-to-cell
communication
CRC
microenvironment.
Lastly,
propose
potential
manipulate
enhance
anti-tumor
thereby
underlining
significance
devising
innovative
interventions
CRC.
